Trials / Completed
CompletedNCT00999271
Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism
On the Role of Glucose-dependent Insulinotropic Polypeptide, GIP, in Postprandial Metabolism in Humans
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (planned)
- Sponsor
- Hvidovre University Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The aim of this proposal is to examine whether endogenous GIP and exogenous GIP alone and in combination with insulin affect gastric emptying (GE), appetite, energy intake, energy expenditure (EE) and plasma levels of triglycerides (TAG), free fatty acids FFA) and glycerol in man.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP) | two different dosages: * 0.8 pmol/kg/min * 1.5 pmol/kg/min for 300 minutes |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-10-21
- Last updated
- 2009-10-21
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00999271. Inclusion in this directory is not an endorsement.